Why the Earnings Streak Will Continue for GATX Corporation (GATX)

Looking for a stock that might be in a good position to beat earnings at its next report? Consider GATX Corporation GATX, a firm in the Transportation – Equipment and Leasing industry, which could be a great candidate for another beat.

This company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. In fact, in these reports, GATX has beaten estimates by at least 20% in both cases, suggesting it has a nice short-term history of crushing expectations.

Earnings in Focus

Two quarters ago, GATX was expected to post $1.10 per share, while it actually produced $1.32 per share, a beat of 20%. Meanwhile, for the most recent quarter, the company looked to deliver 99 cents per share, when it actually saw $1.25 per share instead, representing a 26.3% positive surprise.

Thanks in part to this history, recent estimates have been moving higher for GATX Corporation. In fact, the Earnings ESP for GATX is positive, which is a great sign of a coming beat.

After all, the Zacks Earnings ESP compares the most accurate estimate to the broad consensus, looking to find stocks that have seen big revisions as of late, suggesting that analysts have recently become more bullish on the company’s earnings prospects. This is the case for GATX, as the firm currently has a Zacks Earnings ESP of 8.33%, so another beat could be around the corner.

This is particularly true when you consider that GATX has a great Zacks Rank #2 (Buy), which can be a harbinger of outperformance and a signal for a strong earnings profile. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

When you add this solid Zacks Rank to a positive Earnings ESP, a positive earnings surprise happens nearly 70% of the time, so it seems pretty likely that GATX could see another beat at its next report, especially if recent trends are any guide.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research